| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Alginate synthesis and antifungal agent delivery carriers. L-Trigluronic acid is a building block for alginate, which can be used as a carrier for antifungal agents.
|
|---|---|
| ln Vitro |
β-d-mannuronic acid (M) and α-l-guluronic acid (G) polyanionic polysaccharides are collectively referred to as alginate. Alginate has MMM and GGG chain homosequences interspersed with MGM heterosequences, connected by a 1→4 linkage[1]. Because of its non-toxic, biodegradable, biocompatible, mucoadhesive, and non-immunogenic qualities, alginate is frequently utilized to create drug delivery systems. Furthermore, there is a lot of promise for treating fungal infections in vivo with alginate-based antifungal delivery systems[1].
As a polysaccharide building block, L-Trigluronic acid is used in the synthesis of alginate. Alginate can be utilized as a carrier for antifungal agents. No direct biological activity as a drug has been reported. |
| ln Vivo |
No in vivo activity data has been reported for L-Trigluronic acid. As a polysaccharide building block for alginate synthesis, it is primarily used as a research material for drug delivery applications.
|
| Enzyme Assay |
L-Trigluronic acid is used as a starting material or building block for alginate synthesis. The polymerization of L-guluronic acid units to form alginate can be monitored by HPLC, NMR, or mass spectrometry. The resulting alginate can be characterized for its molecular weight, composition, and gelation properties.
|
| Cell Assay |
L-Trigluronic acid is used in cell-free or cell-based assays to study alginate formation and its properties as a drug delivery carrier. Alginate gels can be evaluated for their ability to encapsulate and release antifungal agents. Biocompatibility can be assessed using cell culture models.
|
| Animal Protocol |
Animal models could be used to evaluate alginate-based formulations for antifungal agent delivery. Efficacy would be assessed by antifungal activity and pharmacokinetic properties of the encapsulated drug.
|
| ADME/Pharmacokinetics |
L-Trigluronic acid has a molecular weight of 546.39 and a molecular formula of C1₈H2₆O1₉. It is a linear polysaccharide copolymer. Purity: ≥95% or ≥98%. Storage: cool, dry place.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published for L-Trigluronic acid. As a polysaccharide building block, it is generally considered biocompatible. Comprehensive toxicological studies have not been performed.
|
| References |
[1]. Cristina de Castro Spadari, et al. Potential Use of Alginate-Based Carriers As Antifungal Delivery System.Front Microbiol. 2017 Jan 30;8:97.
[2]. R.A. Shirwaiker, et al. L-Guluronic Acid |
| Additional Infomation |
L-Trigluronic acid is a linear polysaccharide copolymer consisting of three L-guluronic acid units. It is used for the synthesis of alginate, which can be utilized in research on antifungal agent delivery carriers. The compound is for research use only.
|
| Molecular Formula |
C18H26O19
|
|---|---|
| Molecular Weight |
546.388
|
| Exact Mass |
546.106
|
| CAS # |
66754-14-1
|
| Related CAS # |
L-Tetraguluronic acid;149511-37-5;L-Pentaguluronic acid;183668-72-6;L-Hexaguluronic acid;183668-74-8;L-Diguluronic acid;34044-54-7
|
| PubChem CID |
91857798
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
-6.1
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
853
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
[C@@H]1([C@@H]([C@@H](O[C@H]([C@H]1O)O[C@H]2[C@@H]([C@@H]([C@@H](O[C@H]2C(=O)O)O[C@H]3[C@@H]([C@@H]([C@@H](O[C@H]3C(=O)O)O)O)O)O)O)C(=O)O)O)O
|
| InChi Key |
LCLHHZYHLXDRQG-KNQRCHRCSA-N
|
| InChi Code |
InChI=1S/C18H26O19/c19-1-2(20)10(13(26)27)36-17(6(1)24)35-9-4(22)7(25)18(37-12(9)15(30)31)34-8-3(21)5(23)16(32)33-11(8)14(28)29/h1-12,16-25,32H,(H,26,27)(H,28,29)(H,30,31)/t1-,2-,3+,4+,5-,6-,7-,8-,9-,10+,11+,12+,16+,17+,18+/m0/s1
|
| Chemical Name |
(2R,3S,4S,5S,6R)-6-[(2R,3S,4R,5S,6R)-2-carboxy-6-[(2R,3S,4R,5S,6R)-2-carboxy-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 250 mg/mL (457.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8302 mL | 9.1510 mL | 18.3019 mL | |
| 5 mM | 0.3660 mL | 1.8302 mL | 3.6604 mL | |
| 10 mM | 0.1830 mL | 0.9151 mL | 1.8302 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
